MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Coherus Biosciences Inc

Chiusa

SettoreSettore sanitario

0.8 3.9

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.79

Massimo

0.8

Metriche Chiave

By Trading Economics

Entrata

-5.9M

-57M

Vendite

-47M

7.6M

P/E

Media del settore

1.662

40.527

EPS

-0.35

Margine di Profitto

-744.427

Dipendenti

221

EBITDA

115K

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+397.53% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-33M

85M

Apertura precedente

-3.1

Chiusura precedente

0.8

Notizie sul Sentiment di mercato

By Acuity

50%

50%

115 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 lug 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 15:57 UTC

Discorsi di Mercato

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 lug 2025, 15:49 UTC

Discorsi di Mercato

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Received All Required Authorizations

4 lug 2025, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 lug 2025, 15:46 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 lug 2025, 14:30 UTC

Acquisizioni, Fusioni, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 lug 2025, 13:53 UTC

Discorsi di Mercato

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

4 lug 2025, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 lug 2025, 12:30 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 lug 2025, 12:15 UTC

Discorsi di Mercato

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 lug 2025, 12:13 UTC

Discorsi di Mercato

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 lug 2025, 12:02 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

397.53% in crescita

Previsioni per 12 mesi

Media 4.03 USD  397.53%

Alto 7 USD

Basso 1.05 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

115 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.